Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naveen Karkada

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|April 9, 2024
Dynamic borrowing of historical controls adjusting for covariates in vaccine efficacy clinical trialsAndrea Callegaro, Yongyi Luo, Naveen Karkada, et al.
Pharmaceutical Statistics|January 6, 2023
Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studiesAndrea Callegaro, Naveen Karkada, Emmanuel Aris, et al.
Statistical Methods in Medical Research|January 28, 2021
Inference under covariate-adaptive randomization: A simulation studyAndrea Callegaro, B S Harsha Shree, Naveen Karkada
Human Vaccines & Immunotherapeutics|September 23, 2016
Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysisHtay Htay Han, Naveen Karkada, Girish Jayadeva, et al.
Human Vaccines & Immunotherapeutics|September 20, 2013
The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicityHubert Buyse, Carlota Vinals, Naveen Karkada, et al.
Expert Review of Vaccines|February 12, 2019
Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine typesMartin Ryser, Valérie Berlaimont, Naveen Karkada, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 29, 2018
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling AnalysisEdouard Ledent, Hugo Arlegui, Hubert Buyse, et al.
Human Vaccines & Immunotherapeutics|August 6, 2016
Post-marketing safety surveillance conducted in Korea (2008-2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™)Son Moon Shin, Chun Soo Kim, Naveen Karkada, et al.
Infectious Diseases and Therapy|July 26, 2020
Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in ChildrenAshish Agrawal, Shafi Kolhapure, Anar Andani, et al.
Contemporary Clinical Trials|December 31, 2016
Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254-258Nicolas Folschweiller, Valérie Berlaimont, S Rachel Skinner, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|April 9, 2024
Dynamic borrowing of historical controls adjusting for covariates in vaccine efficacy clinical trialsAndrea Callegaro, Yongyi Luo, Naveen Karkada, et al.
Pharmaceutical Statistics|January 6, 2023
Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studiesAndrea Callegaro, Naveen Karkada, Emmanuel Aris, et al.
Statistical Methods in Medical Research|January 28, 2021
Inference under covariate-adaptive randomization: A simulation studyAndrea Callegaro, B S Harsha Shree, Naveen Karkada
Human Vaccines & Immunotherapeutics|September 23, 2016
Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysisHtay Htay Han, Naveen Karkada, Girish Jayadeva, et al.
Human Vaccines & Immunotherapeutics|September 20, 2013
The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicityHubert Buyse, Carlota Vinals, Naveen Karkada, et al.
Expert Review of Vaccines|February 12, 2019
Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine typesMartin Ryser, Valérie Berlaimont, Naveen Karkada, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 29, 2018
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling AnalysisEdouard Ledent, Hugo Arlegui, Hubert Buyse, et al.
Human Vaccines & Immunotherapeutics|August 6, 2016
Post-marketing safety surveillance conducted in Korea (2008-2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™)Son Moon Shin, Chun Soo Kim, Naveen Karkada, et al.
Infectious Diseases and Therapy|July 26, 2020
Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in ChildrenAshish Agrawal, Shafi Kolhapure, Anar Andani, et al.
Contemporary Clinical Trials|December 31, 2016
Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254-258Nicolas Folschweiller, Valérie Berlaimont, S Rachel Skinner, et al.
Pageof 4